Catalent Inc Stock Research

Market Summary

USD65.94+1.27

Delayedas of 31 Mar 2023, 12:16 pm

1.96%

CTLT Stock Price

CTLT RSI Chart

CTLT Valuation

Market Cap

11.6B

Price/Earnings (Trailing)

28.39

Price/Sales (Trailing)

2.45

EV/EBITDA

20.26

Price/Free Cashflow

-31.38

CTLT Price/Sales (Trailing)

CTLT Profitability

EBT Margin

10.59%

Return on Equity

8.35%

Return on Assets

3.68%

Free Cashflow Yield

-3.19%

CTLT Fundamentals

CTLT Revenue

Revenue (TTM)

4.8B

Revenue Y/Y

-5.59%

Revenue Q/Q

12.43%

CTLT Earnings

Earnings (TTM)

410.0M

Earnings Y/Y

-16.49%

Earnings Q/Q

-100%

Price Action

52 Week Range

40.69115.34

(Low)(High)

Last 7 days

0.0%

Last 30 days

-5.2%

Last 90 days

43.7%

Trailing 12 Months

-41.6%

CTLT Financial Health

Current Ratio

1.91

Debt/Equity

0.86

Debt/Cashflow

0.08

CTLT Investor Care

Shares Dilution (1Y)

5.24%

Diluted EPS (TTM)

2.27

Peers (Alternatives to Catalent)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	403.2B	94.9B	0.11%	-12.25%	22.47	4.25	1.25%	-14.07%
LLY	306.9B	28.5B	9.47%	18.63%	49.14	10.75	0.79%	11.88%
MRK	272.8B	59.3B	0.39%	32.42%	17.88	4.63	21.72%	11.27%
PFE	226.4B	100.3B	-0.47%	-21.10%	7.22	2.26	23.43%	42.74%
BMY	145.0B	46.2B	-1.10%	-5.44%	22.92	3.14	-0.49%	-9.54%
MID-CAP
PRGO	4.8B	4.5B	-6.08%	-6.58%	-33.89	1.07	7.56%	-104.06%
RETA	3.3B	2.2M	188.80%	191.52%	-10.55	1.5K	-80.71%	-4.88%
SMALL-CAP
SUPN	1.9B	667.2M	-3.51%	11.94%	31.82	2.89	15.09%	13.64%
TLRY	1.6B	602.5M	-7.75%	-62.41%	-2.73	2.62	18.18%	-18.59%
CGC	855.6M	478.9M	-23.48%	-77.89%	-0.27	1.79	-31.50%	-634.70%
INVA	771.4M	285.2M	-7.62%	-41.93%	3.5	2.7	-27.21%	-40.28%
CRON	719.3M	114.5M	-12.90%	-53.56%	-4.26	6.28	27.90%	57.40%
ACRS	555.5M	29.8M	-33.15%	-52.78%	-6.39	18.67	340.05%	4.35%
OCUL	398.4M	51.5M	-14.57%	2.18%	-5.61	7.74	18.32%	-984.05%
ENDP	94.1M	2.3B	-43.99%	-88.43%	-0.03	0.04	-22.53%	-376.66%

Financials for Catalent

* denotes actual numbers (not divided by Millions)
Income Statement (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	-1.4%	4,757	4,825	4,828	4,703	4,483
Gross Profit	-1.1%	1,556	1,574	1,640	1,591	1,534
S&GA Expenses	-0.2%	855	857	844	802	768
R&D Expenses	-4.3%	22.00	23.00	24.00	21.00	-
EBITDA	-1.4%	761	772	860	843	-
EBITDA Margin	0.0%	0.16*	0.16*	0.18*	0.18*	-
Earnings Before Taxes	-0.2%	504	505	605	615	756
EBT Margin	1.2%	0.11*	0.10*	0.13*	0.13*	-
Interest Expenses	-11.6%	-144	-129	-123	-123	-117
Net Income	-3.8%	410	426	519	513	604
Net Income Margin	-2.4%	0.09*	0.09*	0.11*	0.11*	-
Free Cahsflow	21.2%	-371	-471	-221	-110	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	9.2%	11,147	10,205	10,507	10,322	10,203
Current Assets	8.2%	2,918	2,698	2,916	3,025	2,974
Cash Equivalents	57.3%	442	281	449	786	849
Inventory	11.7%	818	732	702	676	688
Net PPE	13.0%	3,579	3,167	3,127	2,820	2,727
Goodwill	9.8%	3,215	2,929	3,006	3,012	3,026
Liabilities	13.3%	6,235	5,505	5,712	5,690	5,722
Current Liabilities	61.8%	1,526	943	1,072	1,046	1,045
Long Term Debt	3.0%	4,221	4,098	4,171	4,157	4,191
Shareholder's Equity	4.5%	4,912	4,700	4,795	4,632	4,481
Retained Earnings	15.1%	619	538	538	350	209
Additional Paid-In Capital	0.3%	4,686	4,674	4,649	4,630	4,615
Accumulated Depreciation	7.9%	1,465	1,358	1,347	1,308	1,215
Shares Outstanding	0%	180	180	179	179	171
Float	-	21,840	-	-	-	-

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	78.8%	329	184	439	504	441
Share Based Compensation	-1.9%	51.00	52.00	54.00	55.00	60.00
Cashflow From Investing	28.6%	-1,309	-1,833	-1,884	-1,703	-1,594
Cashflow From Financing	2487.0%	595	23.00	1,031	1,013	1,182

Risks for CTLT

What is the probability of a big loss on CTLT?

65.4%

Probability that Catalent stock will be more than 20% underwater in next one year

55.8%

Probability that Catalent stock will be more than 30% underwater in next one year.

10.8%

Probability that Catalent stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CTLT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Catalent was unfortunately bought at previous high price.

Drawdowns

Returns for CTLT

Cumulative Returns on CTLT

13.5%

7-Year Cumulative Returns

9.5%

5-Year Cumulative Returns

8.6%

3-Year Cumulative Returns

What are the long-term rolling returns for CTLT?

FIve years rolling returns for Catalent.

Annualized Returns

Which funds bought or sold CTLT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-27	Neo Ivy Capital Management	added	16,557	282,000	285,000	0.19%
2023-03-23	MetLife Investment Management, LLC	reduced	-0.81	-1,375,980	2,216,470	0.02%
2023-03-17	American Portfolios Advisors	added	5.72	-30,144	74,893	-%
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	added	17.75	-1,463,000	4,004,000	-%
2023-03-06	NORTH STAR ASSET MANAGEMENT INC	added	17.63	-1,140,120	3,109,880	0.19%
2023-03-06	Rockefeller Capital Management L.P.	reduced	-74.97	-6,635,000	1,222,000	0.01%
2023-02-28	Voya Investment Management LLC	added	30.19	-3,101,880	13,205,100	0.02%
2023-02-24	NATIXIS	sold off	-100	-2,339,000	-	-%
2023-02-24	National Pension Service	reduced	-99.98	-18,756,100	2,025	-%
2023-02-22	TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY	unchanged	-	-456,000	752,000	0.01%

Latest Funds Activity

Are funds buying CTLT calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own CTLT

No. of Funds

Catalent News

Schedule 13G FIlings of Catalent

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	t. rowe price investment management, inc.	9.2%	16,578,946	SC 13G/A
Feb 13, 2023	capital world investors	7.7%	13,914,820	SC 13G/A
Feb 09, 2023	janus henderson group plc	4.6%	8,216,242	SC 13G/A
Feb 09, 2023	vanguard group inc	10.88%	19,588,103	SC 13G/A
Feb 07, 2023	blackrock inc.	7.7%	13,788,094	SC 13G/A
Jan 27, 2023	veritas asset management llp	6.21%	11,169,815	SC 13G
Feb 14, 2022	price t rowe associates inc /md/	10.8%	18,616,482	SC 13G/A
Feb 11, 2022	capital world investors	6.2%	10,577,293	SC 13G
Feb 09, 2022	vanguard group inc	10.79%	18,479,271	SC 13G/A
Feb 03, 2022	blackrock inc.	8.8%	14,998,086	SC 13G/A

CTLT Fair Value

Catalent fair value in different scenarios

The table shows the Fair Value estimates for Catalent for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	52.48 -20.41%	66.72 1.19%	94.66 43.57%	131.81 99.91%	165.84 151.52%
Current Inflation	48.38 -26.62%	60.51 -8.23%	83.99 27.38%	115.25 74.79%	143.74 118.00%
Very High Inflation	43.32 -34.30%	53.04 -19.56%	71.45 8.36%	96.07 45.70%	118.36 79.51%

Historical Catalent Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Catalent

View All Filings

Date Filed	Form Type	Document
Feb 21, 2023	3	Insider Trading
Feb 14, 2023	SC 13G/A	Major Ownership Report
Feb 13, 2023	SC 13G/A	Major Ownership Report
Feb 09, 2023	SC 13G/A	Major Ownership Report
Feb 09, 2023	SC 13G/A	Major Ownership Report
Feb 07, 2023	SC 13G/A	Major Ownership Report
Feb 07, 2023	8-K	Current Report
Feb 07, 2023	10-Q	Quarterly Report
Feb 06, 2023	3	Insider Trading
Jan 27, 2023	SC 13G	Major Ownership Report

Latest Insider Trading transactions for CTLT

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-01-23	Hopson Ricky	sold	-31,738	49.36	-643	pres. clinical dev supply div
2022-12-05	Boerman Manja	sold	-40,326	51.7	-780	pres. biomodalities division
2022-10-31	Grippo Michael J	sold	-161,349	65.83	-2,451	svp, strategy & corp. dev.
2022-10-27	Barber Michael J	acquired	-	-	4,149	-
2022-10-27	GREISCH JOHN J	acquired	-	-	4,149	-
2022-10-27	Balachandran Madhavan	acquired	-	-	4,149	-
2022-10-27	MOREL DONALD E JR	acquired	-	-	4,149	-
2022-10-27	CLASSON ROLF A	acquired	-	-	4,149	-
2022-10-27	Kreuzburg Christa	acquired	-	-	4,149	-
2022-10-27	STAHL JACK L	acquired	-	-	4,149	-

About Catalent

John R. Chiminski

www.catalent.com

17300

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

CTLT Income Statement

2022-09-30

Consolidated Statements of Operations - USD ($)
$ in Millions

3 Months Ended

Sep. 30, 2022

Sep. 30, 2021

Income Statement [Abstract]

Net revenue

$ 1,022.0

$ 1,025.0

Cost of sales

764.0

701.0

Gross margin

258.0

324.0

Selling, general, and administrative expenses

196.0

183.0

Payments for (Proceeds from) Businesses and Interest in Affiliates

^[1]

0.0

(1.0)

Other Cost and Expense, Operating

2.0

4.0

Operating earnings

60.0

138.0

Interest expense, net

32.0

26.0

Other (income)/expense, net

^[2]

25.0

9.0

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total

3.0

103.0

Income tax expense

3.0

10.0

Net earnings/(loss)

0.0

93.0

Participating Securities, Distributed and Undistributed Earnings (Loss), Basic

0.0

9.0

Net Income (Loss) Available to Common Stockholders, Basic

$ 0.0

$ 84.0

Earnings Per Share, Basic

$ 0

$ 0.49

Earnings Per Share, Diluted

$ 0

$ 0.49

[1]	Gain on sale of subsidiary for the three months ended September 30, 2021 was due to the sale of the facility in Woodstock, Illinois and the associated business
[2]	Other expense, net during the three months ended September 30, 2022 includes foreign currency remeasurement losses/gains.Other expense, net during the three months ended September 30, 2021 includes financing charges related to the Company’s Incremental Term B-3 Loans and foreign currency remeasurement losses/gains.

CTLT Balance Sheet

2022-09-30

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2022	Jun. 30, 2022
Current assets:
Cash and cash equivalents	$ 281	$ 449
Trade receivables, net	989	1,051
Inventories	732	702
Prepaid expenses and other	632	625
Marketable Securities	64	89
Total current assets	2,698	2,916
Property, plant, and equipment, net	3,167	3,127
Other assets:
Goodwill	2,929	3,006
Other intangibles, net	1,017	1,060
Deferred Income Tax Assets, Net	45	49
Other Assets, Noncurrent	349	349
Total assets	10,205	10,507
Current Liabilities:
Debt, Current	106	31
Accounts payable	379	421
Other accrued liabilities	458	620
Total current liabilities	943	1,072
Long-term obligations, less current portion	4,098	4,171
Pension liability	98	103
Deferred Income Taxes	214	202
Other liabilities	152	164
Total liabilities	5,505	5,712
Temporary Equity, Carrying Amount, Attributable to Parent	$ 0	$ 0
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000
Common Stock, Value, Outstanding	$ 2	$ 2
Preferred Stock, Value, Outstanding	0	0
Additional paid in capital	4,674	4,649
Accumulated deficit	538	538
Accumulated other comprehensive income/(loss)	(514)	(394)
Total shareholders' equity	4,700	4,795
Total liabilities, redeemable preferred stock, and shareholders’ equity	$ 10,205	$ 10,507
Common stock, shares issued (shares)	180,000,000	179,000,000